University of Minnesota

Other

Peter M Anderson

Fatih M Uckun

Kamil Ugurbil

Augusto C Ochoa

Gregor Adriany

Anand Gopinath

Pierre-Francois Van De Moortele

Arnold S Leonard

Cynthia M Loeffler

Keith M Skubitz

Lance Delabarre

Chris Olson

Cytotoxic biotherapeutic agents effective for treating certain types of cancer in humans are provided which comprise the TP-3 murine monoclonal antibody chemically conjugated to pokeweed antiviral protein (PAP). The invention further provides a method which utilizes the disclosed cytotoxic biotherapeutic agents to systemically treat cancer patients. With slight modifications the method of the present invention should be generally applicable to preparation and use of other cytotoxic biotherapeutic agents using chemical or recombinant derivatives of the TP-3 or TP-1 antibodies or PAP toxin. The invention is applicable to cancer patients who express the p80 antigen recognized by the TP-1/TP-3 antibodies either on the surface of their tumor cells or on the tumor blood vessels.

Biotherapy of cancer by targeting TP-3/P80

The present invention provides a liposome comprising an effective immunoadjuvant amount of a lymphokine such as IL-2. Also provided is an effective antineoplastic amount of IL-2 liposomes in combination with adoptively transferred cells stimulated with anti-CD3 monoclonal antibody plus IL-2.

Lipsome containing IL-2

Liposome immunoadjuvants containing IL-2

Glutamine is administered orally at a rate of about 4.5 g/m.sup.2 per day to treat oropharyngeal mucositis. This is administered to patients that experience or may develop oropharyngeal mucositis, especially those caused by chemotherapy or radiotherapy.

Oral glutamine to reduce stomatitis

Growing community of inventors

St. Louis Park, MN, United States of America

Peter M Anderson